Federal Judge Blocks Trump HHS Declaration on Transgender Treatments for Minors
U.S. District Judge Mustafa Kasubhai in Oregon, a 2023 Biden appointee, granted preliminary relief to hospitals and clinicians on March 24, ruling that Health and Human Services Secretary Robert F. Kennedy Jr. exceeded his authority and skipped required rulemaking when he issued a December declaration labeling 'sex-rejecting procedures' for minors as neither safe nor effective. The lawsuit, brought by 20 Democratic-led states and Washington, D.C., challenges the declaration’s attempt to deem puberty blockers, cross-sex hormones and certain surgeries for gender dysphoria in minors as failing 'professionally recognized standards of health care.' Kasubhai rejected the administration’s claim that the document was merely a nonbinding policy statement and said HHS was effectively using a 'break it and see' approach inconsistent with the rule of law, while denying the government’s motion to dismiss. The ruling temporarily bars the federal government from enforcing the declaration against the plaintiff states’ providers while Kasubhai prepares a written opinion that will spell out his legal reasoning in more detail. The case is an early test of how far the Trump administration can go in reclassifying gender-affirming care through executive action, and it underscores the increasingly central role of federal courts in refereeing medical and cultural fights over transgender youth care.
📌 Key Facts
- Judge: U.S. District Judge Mustafa Kasubhai in Oregon, appointed by President Biden in 2023
- Action: Granted preliminary relief to health professionals and denied HHS’s motion to dismiss, blocking enforcement of a December HHS declaration
- Policy at issue: HHS Secretary Robert F. Kennedy Jr.’s December declaration that 'sex-rejecting procedures' for children and adolescents, including puberty blockers, cross-sex hormones and surgeries, are 'neither safe nor effective' and do not meet professionally recognized standards of care
- Plaintiffs: 20 Democratic-led states plus Washington, D.C., all of which permit some form of gender-related medical treatment for minors
- Government stance: DOJ argued the declaration was a nonbinding policy opinion exempt from formal rulemaking requirements; Kasubhai indicated HHS instead used a 'break it and see' approach that overstepped its authority
📊 Relevant Data
The percentage of U.S. high school students identifying as transgender increased to 3.3% in 2023, up from lower rates in previous years, representing approximately 724,000 youth aged 13-17.
How Many Adults and Youth Identify as Transgender in the United States? — Williams Institute, UCLA School of Law
Systematic reviews, such as the UK's Cass Review, have found that the evidence for the benefits of puberty blockers and cross-sex hormones in treating gender dysphoria in minors is of low quality, with little improvement in mental health outcomes.
Cass Review Final Report — Independent Review of Gender Identity Services for Children and Young People
Detransition rates among transgender youth who have undergone medical interventions range from 1% to 8% in recent studies, with some temporary due to external pressures.
Levels of Satisfaction and Regret With Gender-Affirming Medical Care in Adolescents — JAMA Pediatrics
Transgender and gender-diverse youth have autism rates up to 11%, compared to about 1.85% in the general population, indicating a significant co-occurrence.
A comparison of gender diversity in transgender young people with and without autistic traits at UK gender clinic — PMC (National Library of Medicine)
Among transgender youth seeking care, there has been a shift toward more assigned females at birth, with ratios inverting from majority male to majority female in recent cohorts.
Greater gender diversity among autistic children by self-report and parent-report — Autism (SAGE Journals)
Several European countries, including the UK, Finland, and Sweden, have restricted or banned puberty blockers for minors outside clinical trials following evidence reviews like the Cass Review, citing insufficient evidence of benefits.
Europe Adopts A Cautious Approach To Gender-Affirming Care For Minors — Forbes
📰 Source Timeline (1)
Follow how coverage of this story developed over time